Free Trial
NYSEAMERICAN:PTN

Palatin Technologies (PTN) Stock Price, News & Analysis

$1.96
+0.12 (+6.50%)
(As of 06/12/2024 ET)
Today's Range
$1.85
$1.98
50-Day Range
N/A
52-Week Range
$1.43
$5.65
Volume
101,335 shs
Average Volume
486,255 shs
Market Capitalization
$31.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Palatin Technologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
765.1% Upside
$17.00 Price Target
Short Interest
Bearish
8.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Palatin Technologies in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$12,720 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.41) to ($0.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.04 out of 5 stars

PTN stock logo

About Palatin Technologies Stock (NYSEAMERICAN:PTN)

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

PTN Stock Price History

PTN Stock News Headlines

Q3 2024 Palatin Technologies Inc Earnings Call
Palatin Technologies Inc. Q3 Loss Decreases
PTN Apr 2024 2.500 put
See More Headlines
Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2024
Today
6/13/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:PTN
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$17.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+765.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,540,000.00
Net Margins
-445.12%
Pretax Margin
-601.37%

Debt

Sales & Book Value

Annual Sales
$4.85 million
Book Value
$0.01 per share

Miscellaneous

Free Float
14,991,000
Market Cap
$31.72 million
Optionable
Not Optionable
Beta
0.93
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Carl Spana Ph.D. (Age 62)
    Co-Founder, President, CEO & Director
    Comp: $979k
  • Mr. Stephen T. Wills CPA (Age 67)
    MST, CFO, COO, Executive VP, Treasurer & Secretary
    Comp: $910.55k
  • Burns McClellan
    Vice President of Investor Relations
  • Mr. Stephen A. Slusher Esq.
    Chief Legal Officer
  • Dr. Michael B. Raizman M.D.
    Chief Medical Officer
  • Mr. James E. Hattersley (Age 64)
    Senior Vice President of Business Development
  • Mr. John Dodd Ph.D.
    Senior Vice President of Preclinical Development
  • Mr. Robert Jordan
    Senior Vice President of Program Operations

PTN Stock Analysis - Frequently Asked Questions

Should I buy or sell Palatin Technologies stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTN shares.
View PTN analyst ratings
or view top-rated stocks.

What is Palatin Technologies' stock price target for 2024?

1 brokers have issued twelve-month price targets for Palatin Technologies' stock. Their PTN share price targets range from $17.00 to $17.00. On average, they predict the company's share price to reach $17.00 in the next year. This suggests a possible upside of 765.1% from the stock's current price.
View analysts price targets for PTN
or view top-rated stocks among Wall Street analysts.

How have PTN shares performed in 2024?

Palatin Technologies' stock was trading at $4.00 at the start of the year. Since then, PTN shares have decreased by 50.9% and is now trading at $1.9650.
View the best growth stocks for 2024 here
.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) posted its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.03. Palatin Technologies had a negative net margin of 445.12% and a negative trailing twelve-month return on equity of 583.06%. During the same quarter in the prior year, the company posted ($0.63) earnings per share.

When did Palatin Technologies' stock split?

Palatin Technologies shares reverse split before market open on Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:PTN) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners